Lunai Bioworks Inc. (LNAI)
NASDAQ: LNAI · Real-Time Price · USD
0.4300
-0.0500 (-10.42%)
Feb 24, 2026, 10:37 AM EST - Market open
Lunai Bioworks Employees
Lunai Bioworks had 29 employees as of June 30, 2025. The number of employees increased by 4 or 16.00% compared to the previous year.
Employees
29
Change (1Y)
4
Growth (1Y)
16.00%
Revenue / Employee
n/a
Profits / Employee
-$4,328,395
Market Cap
10.40M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 29 | 4 | 16.00% |
| Jun 30, 2024 | 25 | 13 | 108.33% |
| Jun 30, 2023 | 12 | -10 | -45.45% |
| Jun 30, 2022 | 22 | 11 | 100.00% |
| Jun 30, 2021 | 11 | 1 | 10.00% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Longeveron | 25 |
| BioCardia | 20 |
| Soligenix | 16 |
| NewcelX | 15 |
| Akari Therapeutics, | 9 |
| Traws Pharma | 7 |
| Phio Pharmaceuticals | 5 |
| Pulmatrix | 2 |
LNAI News
- 5 days ago - Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping - PRNewsWire
- 11 days ago - Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC - PRNewsWire
- 15 days ago - Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data - PRNewsWire
- 4 weeks ago - Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons - PRNewsWire
- 4 weeks ago - Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery - PRNewsWire
- 2 months ago - Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance - PRNewsWire
- 2 months ago - Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market - PRNewsWire
- 3 months ago - Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models - PRNewsWire